Meridian Bioscience — William Blair Healthcare Conference 2019
26 slides from Meridian Bioscience's conference presentation, Jun 6, 2019
Slide 1: William Blair Healthcare Conference
William Blair Healthcare Conference Jack Kenny, Chief Executive Officer June 6, 2019 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the m
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures Certain financial measures presented in this presentation, such as operating expenses, operating income, net earnings and diluted earnings per share, excluding as applicable the effects of restructuring costs, litigation costs, goodwill impairment charge, and certain one-
Slide 4: What Is Meridian Bioscience?
What Is Meridian Bioscience? 2018 sales: $63M ~185 employees 6 locations in 5 countries Development and production of proprietary antibodies, antigens, and molecular reagents Capacity and expertise to supply high volume, high demand customers International footprint including China LIFE SCIENCE 2018
Slide 5: Meridian Bioscience Overview
FY18 Sales by Platform FY18 Sales by Region Core platforms Molecular (DNA Amplification) Rapid Immunoassay Enzyme-linked Immunoassay Blood Chemistry (Anodic Stripping Voltammetry, LeadCare® brand) Core products Gastrointestinal (H. pylori, C. difficile, EHEC, Campy) Respiratory (Group A Strep, Mycop
Slide 6: Strategic Imperatives
Manage competitive pressures and product life cycles Leverage cost structure and operational efficiency Focus resources on core target markets Redeploy available capital to support investment in the business Increase investment in R&D, acquisitions Strategic Imperatives G G G G G Reposition the busi
Slide 7: Life Science
Life Science eT
Slide 8: Life Science Strategic Summary
Pivot sales focus to high value accounts R&D consolidation: Centers of excellence Move to more cost effective approach to sell into academia (distribution, online, inside sales) Resource Utilization Leverage strong IA position in IVD (and China) to grow MDx Leverage strong MDx position in academia t
Slide 9: Life Science Sample to Bulk Order
Life Science Sample to Bulk Order ORDER VOLUME: Sample Orders Lot Orders Bulk Orders 6-12 months LEAD TIME: 12-24 months Customers Seek Regulatory Approvals Long lead time from sample to full bulk order High and consistent quality critical Sticky business as customers tend to avoid re-validation Str
Slide 10: Life Science Financial Performance
Annual Revenues (millions) Life Science Financial Performance +12% +10% Operating Margin 2019 and Beyond Opportunities: Continued outsourcing by IVD manufacturers New products for both IVD and research applications Growth of MDx market, globally Challenges: Recent shift in China demand environment O
Slide 11: Diagnostics
Diagnostics ~~
Slide 12: Vision and Key Focus Activities
Vision The health system’s (IDNs) trusted partner, spanning the continuum of care from the physician office to the hospital laboratory, delivering expertise and innovation in gastrointestinal disease testing and supporting the well-being of our children to improve health outcomes and build a healthi
Slide 13: Strategic Positioning
Strategic Positioning I D N I D N Physician Office Labs Large Hospitals Medium Hospitals Small Hospitals Allows selling across IDNs (small to large) Allows best-in-class technology for each assay (i.e. C. diff) GI Depth Dual Technology IA + MDx Pediatric POC Workstation Consolidation Allows for deep
Slide 14: Acquisition of GenePOC and revogene Platform
by Molecular Diagnostics Platform Acquisition of GenePOC and revogeneTM Platform
Slide 15: GenePOC Strategic Fit and Rationale
Adds state-of-the-art revogene™ molecular diagnostics platform Ideal fit for deep gastrointestinal and select respiratory strategy GenePOC Strategic Fit and Rationale FDA-cleared / CE-marked menu in place Market-ready to transition Meridian molecular diagnostics customers Strong development and engi
Slide 16: revogene Workflow Sample-to-Answer
Discharge sample Hands on time ~1 minute Collect sample Sample vortexing Load sample into the PIE Place PIE into system and start Results within 70 minutes 1 2 3 revogeneTM Workflow Sample-to-Answer
Slide 17: GenePOC Operational Footprint
R&D Team and Track Record Quebec-based team FDA cleared instrument 4 FDA cleared assays Novel consumable and instrument designs Manufacturing Footprint Pilot PIE assembly line in place since 2013 Used for R&D, RUO, and IUO lots Used for commercial IVD lots Current capacity of 700K PIEs/year/shift Ge
Slide 18: revogene Competitive Positioning
Ease of use # of Multiplex Targets 1-5 11-15 6-10 16-20 21+ Competitor A Simplified sample prep Efficient workflow Multiple sample types Random access PCR technology Multiplexing ability Flexible acquisition options Small footprint Intuitive user interface Bidirectional interface Low maintenance Rel
Slide 19: Platform Differentiators
low high simple complex small large low high FOOTPRINT / SIZE COST / SERVICE DESIGN COST Primary competitors Primary competitors Primary competitors Primary competitors Powerful instrument that fits in many types of customer segments cost-effectively Elegant consumable design with competitive advant
Slide 20: Conversion of Molecular Customers
Sustainably grow the base with menu expansion and increased competitive placements Stabilize and protect base with Alethia conversions Current trend of Meridian molecular revenues GenePOC acquisition Conversion of Molecular Customers All other MDx assays (including CMV and Malaria) C. difficile Grou
Slide 21: Future Menu Positioning
Future Menu Positioning Group B Strep Group A Strep C. difficile Carbapenemase (colony) Current revogeneTM Menu revogeneTM Menu and Potential Limited menu based on most common tests With the number of antibiotic- resistant bugs and therapies increasing, resistance testing is key Menu on both MDx and
Slide 22: Current and Expanded Market Opportunities (U.S.)
I D N I D N $21B 5,900 $32B 8,900 $3B 120,000 (11,700 CLIA) Physician Office Labs Independent Labs LAB Large Hospitals Medium Hospitals Small Hospitals Lab Revenues: Sites: Immunoassay DiaSorin Automated HpSA® ELISA HpSA® Curian™ C. diff | EHEC | Campy | HpSA® | Flu AB Rapids Foodborne | C. diff | H
Slide 23: Financial Trends and Priorities and Direction
Revenue (millions) Financial Trends Operating Income (millions) Life Science profitability and growth foundation Defend and maintain Diagnostics against increasing competitive pressures Accelerating growth with turnover of core Diagnostic products and platforms (2020-2021) Leverage restructuring act
Slide 24: Strategic Imperatives
Manage competitive pressures and product life cycles Leverage cost structure and operational efficiency Focus resources on core target markets Redeploy available capital to support investment in the business Increase investment in R&D, acquisitions G G G G G Reposition the business for sustainable,
Slide 25: Appendix
APPENDIX =~
Slide 26: GAAP to Non-GAAP Reconciliations
Meridian Bioscience, Inc. GAAP to Non-GAAP Reconciliations (In Thousands)
Meridian Bioscience — William Blair Healthcare Conference 2019 on 6ix